Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of formoterol certihaler tiotropium handihaler and tiotropium handihaler in combination with formoterol certihaler in patients with stable chronic obstructive pulmonary disease.

Next Previous
X
Search
Trial Profile

Efficacy and safety of formoterol certihaler tiotropium handihaler and tiotropium handihaler in combination with formoterol certihaler in patients with stable chronic obstructive pulmonary disease.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Formoterol (Primary) ; Tiotropium bromide
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 24 Oct 2011 Actual end date (November 2005) added as reported by ClinicalTrials.gov.
    • 24 Oct 2011 Company Pacira Pharmaceuticals added to the associations filed as reported by ClinicalTrials.gov record.
    • 24 Dec 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top